Interviews

Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.

Part D plans are navigating intensifying pressure from GLP-1 therapies, which combine relatively high per-patient costs with a massive eligible population.

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said.

Lymphomas arise from immune system cells and can create an environment less hospitable to CAR T-cell expansion, explained Kerry Rogers, MD.

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

Mark Makhinson, PharmD, launches Future-Proofing Pharmacy, exploring AI, access, and the health-system pharmacy enterprise of 2035.

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered.

John Anderson, MD, explains why stronger primary care and specialist collaboration are needed in diabetes care.

Institutions need to think more creatively about how they identify and elevate talent, explains Bhavana Bhatnagar, DO.

Marc A. Sala, MD, explains why frequent exacerbations signal it's time to reassess bronchiectasis care, plus the promise of gene-based screening.

Early findings from the CDAF-Relink program highlight gaps in re-engagement, outreach barriers, and opportunities to reconnect patients to care.

Policy makers should vet the methodology behind reported cost savings before trusting the numbers, says Halima Ahmadi-Montecalvo, PhD, MPH.

Drugs that form the backbone of CLL therapy are also used across lymphoma subtypes, explains Adam S. Kittai, MD.

More prediabetes screening, earlier GLP-1/SGLT2 inhibitor use, and broader CGM access in type 2 diabetes are needed, says John Anderson, MD.

Marc A. Sala, MD, explains why long COVID overlaps with respiratory disease and how multidisciplinary care improves diagnosis and treatment.

Marc A. Sala, MD, discusses bronchiectasis awareness gaps, care strategies, and the importance of cross-specialty communication in patient care.

Swarup Kumar, MD, of UConn Health, says iberdomide plus dara-dex fills a niche for relapsed disease in patients who lack access to CAR T or bispecifics.

Paul A. Offit, MD, explains how the FDA and CDC scrutinize vaccine data before recommending a new vaccine for public use.

Adaptive trials like I-SPY have lifted breast cancer complete response rates to 50%–60%, but better early end points are needed for wider use.

ADCs and oral SERDs are reshaping breast cancer care, easing toxicity but adding new sequencing, HER2 testing, and adherence challenges.

Hepatitis B re-engagement efforts are underreported in lower-resource settings, highlighting gaps in care and the need for greater action.

An expert discusses gaps in pediatric alopecia areata evidence, missed trial outcomes, and what managed care should change for children with the disease.

Diet, alcohol, and physical activity offer actionable targets for clinicians managing MASLD, according to Zobair M. Younossi, MD.

Closed-loop referral systems confirm outcomes, not just referrals, avoiding false success and building durable, scalable social care infrastructure.

Lidia Schapira, MD, Stanford, urges care teams to weigh quality of life, not just scans, in long-term cancer therapy decisions.

She frames the IberDd approval as more than the addition of 1 more regimen to a crowded relapsed/refractory myeloma armamentarium.